Oxandrolone (Anavar)

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Oxandrolone (Anavar)

An anabolic steroid FDA-approved for protein catabolism secondary to corticosteroids and osteoporosis-related bone pain.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Oxandrolone is an anabolic steroid approved by the FDA as adjunctive therapy to offset protein catabolism from prolonged corticosteroid administration and for relief of bone pain from osteoporosis. A boxed warning notes serious risks including liver damage, lipid changes, accelerated bone maturation in children, and bleeding interactions with warfarin.

Benefits reported in the imported source

• Protein-catabolic states secondary to prolonged corticosteroid use.
• Bone pain relief in osteoporosis.

Risks and limits

• Boxed warning: liver toxicity including peliosis hepatis and liver tumors
• Significant lipid changes (decreased HDL, increased LDL)
• Accelerated epiphyseal closure in children
• Hepatotoxicity and cholestatic jaundice
• Increased bleeding risk with warfarin

Source bottom line: FDA-approved for specific catabolic and pain indications with a boxed warning for serious hepatic and cardiovascular risks requiring medical supervision.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 9.4–10.4 hours. Miller & Btaiche 2009, Pharmacotherapy 29(2):213-226, PMID 19170590 Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Label: OXANDROLONE tablet - DailyMed
• StatPearls - Oxandrolone (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)